Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Gains from Investment Securities: 2021-2024

Historic Gains from Investment Securities for Cidara Therapeutics (CDTX) over the last 3 years, with Dec 2024 value amounting to $276,000.

  • Cidara Therapeutics' Gains from Investment Securities changed negligibly% to $50,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $276,000, marking a year-over-year decrease of 92.92%. This contributed to the annual value of $276,000 for FY2024, which is 92.83% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Gains from Investment Securities of $276,000 as of FY2024, which was down 92.83% from $3.8 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Gains from Investment Securities ranged from a high of $3.8 million in FY2023 and a low of $276,000 during FY2024.
  • Over the past 2 years, Cidara Therapeutics' median Gains from Investment Securities value was $2.1 million (recorded in 2023), while the average stood at $2.1 million.
  • Data for Cidara Therapeutics' Gains from Investment Securities shows a maximum YoY tumbled of 92.83% (in 2024) over the last 5 years.
  • Over the past 3 years, Cidara Therapeutics' Gains from Investment Securities (Yearly) stood at $2.3 million in 2021, then reached $3.8 million in 2023, then plummeted by 92.83% to $276,000 in 2024.